Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30115827 | 0.87 | NR1H2 (0.49) | NR1H2ALDH1A1USP2SMN1; SMN2MEN1 | |
| SCHEMBL29153129 | 0.81 | TSHR (0.37) | SMN1; SMN2KDM4E | |
| SCHEMBL29153128 | 0.81 | TSHR (0.37) | SMN1; SMN2KDM4E | |
| SCHEMBL30390162 | 0.79 | NR1H2 (0.40) | NR1H2ALDH1A1USP2SMN1; SMN2MEN1 | |
| SCHEMBL21876568 | 0.79 | HSD11B1 (0.38) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4257940 | 0.79 | HSD11B1 (0.38) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22128606 | 0.78 | PLA2G10 (0.35) | NR1H2PLA2G10PLA2G5 | |
| SCHEMBL10220897 | 0.78 | NR1H2 (0.47) | NR1H2ALDH1A1USP2SMN1; SMN2MEN1 | |
| SCHEMBL335294 | 0.78 | NR1H2 (0.47) | NR1H2ALDH1A1USP2SMN1; SMN2MEN1 | |
| SCHEMBL29170246 | 0.78 | NR1H2 (0.47) | NR1H2ALDH1A1USP2SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | NR1H2 86/4885PLA2G10 3687/4885PLA2G5 1964/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | NR1H2 86/4885PLA2G10 3687/4885PLA2G5 1964/4885 |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | NR1H2 86/4885PLA2G10 3687/4885PLA2G5 1964/4885 |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | NR1H2 86/4885PLA2G10 3687/4885PLA2G5 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.